• news.cision.com/
  • Klaria Pharma Holding AB/
  • Klaria Pharma Holding AB: Klaria publishes prospectus relating to the rights issue and gives update regarding the level of undertaking of the rights issue
English

Klaria Pharma Holding AB: Klaria publishes prospectus relating to the rights issue and gives update regarding the level of undertaking of the rights issue

Report this content

Klaria Pharma Holding AB (”Klaria” or the “Company") today announces that the prospectus relating to the Company's rights issue (the "Rights Issue") has been approved and registered by the Swedish Financial Supervisory Authority (the “SFSA”, sw. Finansinspektionen) (the "Prospectus"). The Company also announces that the Rights Issue of up to SEK 74.0 M before issuing costs has been secured up to 80 per cent by an increased top guarantee undertaking.

Publication of the prospectus

The prospectus that Klaria has prepared due to the upcoming rights issue has today been approved and registered by the SFSA. The Prospectus, containing complete terms and instructions, and application forms can be obtained on Klaria's website (www.klaria.com) and Erik Penser Bank's website (www.penser.se). The prospectus will also be available at the SFSA's website (www.fi.se).

Undertaking

Klaria has by an increased top guarantee undertaking, now amounting to SEK 11 M secured the Rights Issue to approximately 80 per cent, corresponding to SEK 59.2 M. This brings the costs of the Rights Issue to increase with approximately SEK 0.1 M to approximately SEK 10.5 M, whereof guarantee remuneration amounts to approximately SEK 6.2 M.

Summary of the Rights Issue

  • In the Rights Issue a maximum of 59,166,957 shares can be issued that will provide Klaria with up to SEK 74.0 M before issue costs that are estimated to amount to SEK approximately 10.5 M, of which guarantee remuneration amounts to approximately SEK 6.2 M.
  • The subscription price per share amounts to SEK 1.25.
  • Preliminary time plan for the Rights Issue
    • December 5, 2022 Record date to receive subscription rights in the Rights Issue
    • December 7 – 16, 2022 Trading period with subscription rights on Nasdaq First North Growth Market
    • December 7 – 21, 2022 Subscription period
    • December 22, 2022 Announcement of the outcome in the Rights Issue

Advisors

In connection with the Rights Issue, Klaria has hired Erik Penser Bank AB and Setterwalls Advokatbyrå AB as financial and legal advisers.

For more information, please contact:

Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)

investor.relations@klaria.com(scott.boyer@klaria.com)

Tel: 08-446 42 99

For more information, visit the  Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99

 

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.

Subscribe

Documents & Links